Surgical Margins in Breast-Conservation Operations for Invasive Carcinoma: Does Neoadjuvant Chemotherapy Have an Impact?

Journal of the American College of Surgeons

Volumn 206, Issue 6, 2008, Pages 1116-1121

  Soucy, Geneviève ^a   Bélanger, Julie ^a   Leblanc, Guy ^a   Sideris, Lucas ^a   Drolet, Pierre ^a   Mitchell, Andrew ^a   Leclerc, Yves E ^a   Dufresne, Michel P ^a   Beaudet, Julie ^a   Dubé, Pierre ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; BREAST TUMOR; CANCER RISK; CANCER STAGING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LOGISTIC MODELS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES;

EID: 43849100478     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2007.12.025     Document Type: Article

References (27)

1. Schwartz G.F., and Hortobagyi G.N. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 100 (2004) 2512-2532
2. Kaufmann M., Hortobagyi G.N., Goldhirsch A., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24 (2006) 1940-1949
3. Chen A.M., Meric-Bernstam F., Hunt K.K., et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. J Clin Oncol 22 (2004) 2303-2312
4. Chen A.M., Meric-Bernstam F., Hunt K.K., et al. Breast conservation after neoadjuvant chemotherapy. Cancer 103 (2005) 689-695
5. Gentilini O., Intra M., Gandini S., et al. Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome. J Surg Oncol 94 (2006) 375-379
6. Huston T.L., and Simmons R.M. Locally recurrent breast cancer after conservation therapy. Am J Surg 189 (2005) 229-235
7. Sachelarie I., Grossbard M.L., Chadha M., et al. Primary systemic therapy of breast cancer. Oncologist 11 (2006) 574-589
8. Fukutomi T. Clinical practice and outcome of breast-conserving treatment: the effectiveness of preoperative systemic chemotherapy. Breast Cancer 13 (2006) 147-151
9. th ed. (2006), Lippincott Williams and Wilkins, Houston
10. The World Health Organization histological typing of breast tumors-second edition. The World Health Organization. Am J Clin Pathol 78 (1982) 806-816
11. Lyman G.H., Giuliano A.E., Somerfield M.R., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23 (2005) 7703-7720
12. Fisher B., Bauer M., Margolese R., et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312 (1985) 665-673
13. Sadetzki S., Oberman B., Zipple D., et al. Breast conservation after neoadjuvant chemotherapy. Ann Surg Oncol 12 (2005) 480-487
14. van der Hage J.A., van de Velde C.J., Julien J.P., et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19 (2001) 4224-4237
15. Loibl S., von Minckwitz G., Raab G., et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol 13 (2006) 1434-1442
16. Rouzier R., Extra J.M., Carton M., et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 19 (2001) 3828-3835
17. Singletary S.E. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg 184 (2002) 383-393
18. Tartter P.I., Bleiweiss I.J., and Levchenko S. Factors associated with clear biopsy margins and clear reexcision margins in breast cancer specimens from candidates for breast conservation. J Am Coll Surg 185 (1997) 268-273
19. Luu H.H., Otis C.N., Reed Jr. W.P., et al. The unsatisfactory margin in breast cancer surgery. Am J Surg 178 (1999) 362-366
20. Smitt M.C., and Horst K. Association of clinical and pathologic variables with lumpectomy surgical margin status after preoperative diagnosis or excisional biopsy of invasive breast cancer. Ann Surg Oncol 14 (2007) 1040-1044
21. Chagpar A.B., Martin II R.C., Hagendoorn L.J., et al. Lumpectomy margins are affected by tumor size and histologic subtype but not by biopsy technique. Am J Surg 188 (2004) 399-402
22. Moore M.M., Borossa G., Imbrie J.Z., et al. Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy. Ann Surg 231 (2000) 877-882
23. Tubiana-Hulin M., Stevens D., Lasry S., et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 17 (2006) 1228-1233
24. Cocquyt V.F., Blondeel P.N., Depypere H.T., et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 29 (2003) 361-367
25. Newman L.A., Buzdar A.U., Singletary S.E., et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol 9 (2002) 228-234
26. Cristofanilli M., Gonzalez-Angulo A., Sneige N., et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23 (2005) 41-48
27. Mathieu M.C., Rouzier R., Llombart-Cussac A., et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 40 (2004) 342-351